表柔比星分别联合多西紫杉醇与长春瑞滨治疗晚期乳腺癌患者的疗效观察及对患者的预后生存分析

目的观察表柔比星分别联合多西紫杉醇与长春瑞滨治疗晚期乳腺癌患者的临床疗效及对患者预后生存影响。方法前瞻性选取2017年1月到2020年1月在池州市人民医院接受治疗的60例晚期乳腺癌患者,按随机抽样法将其分为研究组与对照组,每组各30例。研究组给予表柔比星联合多西紫杉醇治疗,对照组给予表柔比星联合长春瑞滨治疗,2组患者均干预4~6个周期。比较2组患者临床疗效、不良反应情况、预后生存质量情况。结果研究组与对照组患者疾病治疗有效率(43.33%vs.36.67%)、疾病控制率(90.00%vs.86.67%),差异无统计学意义(P>0.05)。2组患者恶心呕吐(63.33%vs.60.00%)、脱发(90.00%vs.86.67%)、胃肠道反应(66.67%vs.63.33%)、中性细胞下降情况(86.67%vs.83.33%)比较,差异无统计学意义(P>0.05)。研究组外周静脉炎率(33.33%)低于对照组(86.67%),差异有统计学意义(P<0.05)。研究组与对照组患者Karnofsky的行为表现量表(KPS)评分提高率比较(80.00%vs.76.67%),差异无统计学意义(P>0.05)。结论晚期乳腺癌患者使用表柔比星联合多西紫杉醇或者表柔比星联合长春瑞滨治疗,疾病治疗有效率与疾病控制率无明显差异,均能有效改善患者预后生存质量,但是表柔比星联合长春瑞滨治疗外周静脉炎率较高,治疗时要做好相应护理干预,有效预防药物发生外渗。

Efficacy observation of epirubicin combined with docetaxel and vinorelbine in the treatment of advanced breast cancer patients and the prognostic survival analysis of patients

Objective To observe the treatment status of patients with advanced breast cancer,the use of epirubicin combined with docetaxel and vinorelbine treatment,to observe and analyze the clinical efficacy of the above program and the impact on the prognosis of patients.Methods Sixty patients with advanced breast cancer who were treated in Chizhou people's Hospital from January 2017 to January 2020 were prospectively selected and divided into study group and control group according to random sampling method.The study group was treated with epirubicin combined with docetaxel,and the control group was treated with epirubicin combined with vinorelbine.The two groups were intervened for 4~6 cycles,and the clinical efficacy,adverse reactions and prognosis were compared There are many problems.Results The effective rate of disease treatment(43.33%vs.36.67%)and disease control rate(90.00%vs.86.67%)between the study group and the control group were not statistically significant(P>0.05).Nausea and vomiting(63.33%vs.60.00%),alopecia(90.00%vs.86.67%),gastrointestinal reactions(66.67%vs.63.33%),neutrophil decline(86.67%vs.83.33%)in comparison,the difference was not statistically significant(P>0.05).The peripheral phlebitis rate of the study group(33.33%)was lower than that of the control group(86.67%),the difference was statistically significant(P<0.05).The improvement rate of Karnofsky Performance Status(KPS)score between the study group and the control group was compared(80.00%vs.76.67%),and the difference was not statistically significant(P>0.05).Conclusion In the treatment of advanced breast cancer patients with epirubicin combined with docetaxel or epirubicin combined with vinorelbine,there is no significant difference between the effective rate of disease treatment and the disease control rate,can effectively improve the prognostic quality of life of patients,but epirubicin combined with vinorelbine treatment,the peripheral phlebitis rate is higher,and the corresponding nursing intervention should be done to effectively prevent drug extravasation.